Psilocybin causes sex, time, and dose dependent alterations in brain signaling pathways
bioRxiv (Cold Spring Harbor Laboratory) December 17, 2024 J. Hudson Barnett, Kennedi T. Todd, Joseph Benetatos et al. 1 citation preprint
Abstract Psilocybin is a psychedelic tryptamine that has emerged as a potential candidate for the treatment of a variety of conditions, including treatment resistant depression and post-traumatic stress disorder. Clinical trials which have assessed the efficacy of psilocybin for these conditions report a rapid and sustained improvement in patient- and clinician-rated depression scores. The...